None have been approved by the Food and Drug Administration so far, though in 2019, Johnson & Johnson received FDA permission ...

Roughly one in ten Americans suffers from major depressive disorder (MDD) at any given time. In total, up to 20 percent of ...

What if the best medicine isn’t a pill, but people? Discover how community, connection, and shared purpose are transforming ...

Earlier identification is also of interest due to the possibility that earlier intervention may be more effective with more ...

USC and UCLA researchers have created a wireless device that uses AI to decode pain levels from brain activity and customize ...

Depression is everywhere these days, but mental health professionals are not. Some alternative treatments that could help are ...

Depression and anxiety are the most common psychiatric disorders in the world. Around 300 million people suffer from ...

Compass Pathways said Monday it achieved its primary endpoint in an early readout from the largest-ever study of psilocybin ...

An experimental psychedelic therapy from the U.K. company Beckley Psytech significantly reduced symptoms of ...

Compared with placebo, pramipexole added to antidepressants reduces symptoms significantly at 12 weeks in treatment-resistant depression, a trial finds.

Introduction Major depressive disorder (MDD) is a major global healthcare challenge. This is, in part, due to the lack of treatment response and chronic course of MDD. Such a course of illness is ...